nodes	percent_of_prediction	percent_of_DWPC	metapath
Lomitapide—ABCB1—Mitoxantrone—lymphatic system cancer	0.143	0.206	CbGbCtD
Lomitapide—CYP3A4—Cytarabine—lymphatic system cancer	0.124	0.18	CbGbCtD
Lomitapide—CYP3A4—Teniposide—lymphatic system cancer	0.122	0.177	CbGbCtD
Lomitapide—ABCB1—Vincristine—lymphatic system cancer	0.0981	0.142	CbGbCtD
Lomitapide—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0854	0.124	CbGbCtD
Lomitapide—ABCB1—Methotrexate—lymphatic system cancer	0.0594	0.086	CbGbCtD
Lomitapide—CYP3A4—Vincristine—lymphatic system cancer	0.0588	0.0851	CbGbCtD
Lomitapide—Neutrophil count decreased—Fludarabine—lymphatic system cancer	0.0169	0.0544	CcSEcCtD
Lomitapide—Blister—Mechlorethamine—lymphatic system cancer	0.00942	0.0304	CcSEcCtD
Lomitapide—Blood potassium decreased—Mitoxantrone—lymphatic system cancer	0.00689	0.0222	CcSEcCtD
Lomitapide—White blood cell count decreased—Mitoxantrone—lymphatic system cancer	0.00526	0.017	CcSEcCtD
Lomitapide—Dermatitis bullous—Mechlorethamine—lymphatic system cancer	0.00516	0.0167	CcSEcCtD
Lomitapide—Transaminases increased—Carmustine—lymphatic system cancer	0.00463	0.0149	CcSEcCtD
Lomitapide—Reaction gastrointestinal—Methotrexate—lymphatic system cancer	0.00391	0.0126	CcSEcCtD
Lomitapide—Hepatotoxicity—Carmustine—lymphatic system cancer	0.00365	0.0118	CcSEcCtD
Lomitapide—Liver function test abnormal—Teniposide—lymphatic system cancer	0.00335	0.0108	CcSEcCtD
Lomitapide—Gamma-glutamyltransferase increased—Mitoxantrone—lymphatic system cancer	0.00318	0.0103	CcSEcCtD
Lomitapide—Drug interaction—Carmustine—lymphatic system cancer	0.00304	0.0098	CcSEcCtD
Lomitapide—Dehydration—Fludarabine—lymphatic system cancer	0.00297	0.00959	CcSEcCtD
Lomitapide—Liver function test abnormal—Fludarabine—lymphatic system cancer	0.00295	0.00952	CcSEcCtD
Lomitapide—Drug interaction—Vincristine—lymphatic system cancer	0.0029	0.00936	CcSEcCtD
Lomitapide—Gait disturbance—Carmustine—lymphatic system cancer	0.00288	0.00932	CcSEcCtD
Lomitapide—Blood bilirubin increased—Mitoxantrone—lymphatic system cancer	0.00277	0.00894	CcSEcCtD
Lomitapide—Hepatic enzyme increased—Mitoxantrone—lymphatic system cancer	0.00277	0.00894	CcSEcCtD
Lomitapide—Gait disturbance—Vincristine—lymphatic system cancer	0.00275	0.00889	CcSEcCtD
Lomitapide—Angina pectoris—Fludarabine—lymphatic system cancer	0.00269	0.00868	CcSEcCtD
Lomitapide—Vertigo—Mechlorethamine—lymphatic system cancer	0.00267	0.00861	CcSEcCtD
Lomitapide—Unspecified disorder of skin and subcutaneous tissue—Mechlorethamine—lymphatic system cancer	0.00251	0.0081	CcSEcCtD
Lomitapide—Infection—Mechlorethamine—lymphatic system cancer	0.00241	0.00777	CcSEcCtD
Lomitapide—Ecchymosis—Mitoxantrone—lymphatic system cancer	0.00237	0.00764	CcSEcCtD
Lomitapide—Skin disorder—Mechlorethamine—lymphatic system cancer	0.00235	0.0076	CcSEcCtD
Lomitapide—Haematuria—Fludarabine—lymphatic system cancer	0.00235	0.00758	CcSEcCtD
Lomitapide—Sinusitis—Fludarabine—lymphatic system cancer	0.00231	0.00746	CcSEcCtD
Lomitapide—Chills—Teniposide—lymphatic system cancer	0.00226	0.00728	CcSEcCtD
Lomitapide—Decreased appetite—Mechlorethamine—lymphatic system cancer	0.00211	0.0068	CcSEcCtD
Lomitapide—Anaemia—Teniposide—lymphatic system cancer	0.00202	0.00653	CcSEcCtD
Lomitapide—Chills—Fludarabine—lymphatic system cancer	0.00198	0.0064	CcSEcCtD
Lomitapide—Pain in extremity—Vincristine—lymphatic system cancer	0.00195	0.0063	CcSEcCtD
Lomitapide—Malnutrition—Fludarabine—lymphatic system cancer	0.00192	0.00621	CcSEcCtD
Lomitapide—Liver function test abnormal—Carmustine—lymphatic system cancer	0.00189	0.00609	CcSEcCtD
Lomitapide—Haematemesis—Methotrexate—lymphatic system cancer	0.00188	0.00606	CcSEcCtD
Lomitapide—Chest pain—Teniposide—lymphatic system cancer	0.00186	0.00602	CcSEcCtD
Lomitapide—Weight decreased—Bleomycin—lymphatic system cancer	0.00183	0.00591	CcSEcCtD
Lomitapide—Dehydration—Vincristine—lymphatic system cancer	0.00181	0.00586	CcSEcCtD
Lomitapide—Ill-defined disorder—Fludarabine—lymphatic system cancer	0.00178	0.00576	CcSEcCtD
Lomitapide—Anaemia—Fludarabine—lymphatic system cancer	0.00178	0.00574	CcSEcCtD
Lomitapide—Infection—Teniposide—lymphatic system cancer	0.00177	0.00573	CcSEcCtD
Lomitapide—Dehydration—Mitoxantrone—lymphatic system cancer	0.00177	0.00571	CcSEcCtD
Lomitapide—Aspartate aminotransferase increased—Vincristine—lymphatic system cancer	0.00176	0.00567	CcSEcCtD
Lomitapide—Abdominal pain upper—Mitoxantrone—lymphatic system cancer	0.00174	0.0056	CcSEcCtD
Lomitapide—Malaise—Fludarabine—lymphatic system cancer	0.00173	0.0056	CcSEcCtD
Lomitapide—Hyperhidrosis—Teniposide—lymphatic system cancer	0.00173	0.00557	CcSEcCtD
Lomitapide—Haematuria—Bleomycin—lymphatic system cancer	0.00172	0.00556	CcSEcCtD
Lomitapide—Aspartate aminotransferase increased—Mitoxantrone—lymphatic system cancer	0.00171	0.00553	CcSEcCtD
Lomitapide—Hepatotoxicity—Methotrexate—lymphatic system cancer	0.00169	0.00545	CcSEcCtD
Lomitapide—Alanine aminotransferase increased—Mitoxantrone—lymphatic system cancer	0.00168	0.00541	CcSEcCtD
Lomitapide—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00166	0.00535	CcSEcCtD
Lomitapide—Myalgia—Fludarabine—lymphatic system cancer	0.00164	0.00529	CcSEcCtD
Lomitapide—Arthralgia—Fludarabine—lymphatic system cancer	0.00164	0.00529	CcSEcCtD
Lomitapide—Discomfort—Fludarabine—lymphatic system cancer	0.00162	0.00522	CcSEcCtD
Lomitapide—Infection—Fludarabine—lymphatic system cancer	0.00156	0.00504	CcSEcCtD
Lomitapide—Decreased appetite—Teniposide—lymphatic system cancer	0.00155	0.00501	CcSEcCtD
Lomitapide—Vomiting—Mechlorethamine—lymphatic system cancer	0.00154	0.00497	CcSEcCtD
Lomitapide—Nervous system disorder—Fludarabine—lymphatic system cancer	0.00154	0.00497	CcSEcCtD
Lomitapide—Weight decreased—Vincristine—lymphatic system cancer	0.00153	0.00493	CcSEcCtD
Lomitapide—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00152	0.0049	CcSEcCtD
Lomitapide—Weight decreased—Mitoxantrone—lymphatic system cancer	0.00149	0.0048	CcSEcCtD
Lomitapide—Feeling abnormal—Teniposide—lymphatic system cancer	0.00147	0.00475	CcSEcCtD
Lomitapide—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00146	0.00472	CcSEcCtD
Lomitapide—Chills—Bleomycin—lymphatic system cancer	0.00145	0.00469	CcSEcCtD
Lomitapide—Nausea—Mechlorethamine—lymphatic system cancer	0.00144	0.00465	CcSEcCtD
Lomitapide—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00143	0.00462	CcSEcCtD
Lomitapide—Abdominal pain—Teniposide—lymphatic system cancer	0.00141	0.00456	CcSEcCtD
Lomitapide—Body temperature increased—Teniposide—lymphatic system cancer	0.00141	0.00456	CcSEcCtD
Lomitapide—Paraesthesia—Fludarabine—lymphatic system cancer	0.00141	0.00455	CcSEcCtD
Lomitapide—Haematuria—Mitoxantrone—lymphatic system cancer	0.0014	0.00451	CcSEcCtD
Lomitapide—Connective tissue disorder—Carmustine—lymphatic system cancer	0.00139	0.00449	CcSEcCtD
Lomitapide—Dyspepsia—Fludarabine—lymphatic system cancer	0.00138	0.00446	CcSEcCtD
Lomitapide—Hepatic enzyme increased—Methotrexate—lymphatic system cancer	0.00138	0.00445	CcSEcCtD
Lomitapide—Sinusitis—Mitoxantrone—lymphatic system cancer	0.00137	0.00444	CcSEcCtD
Lomitapide—Decreased appetite—Fludarabine—lymphatic system cancer	0.00136	0.00441	CcSEcCtD
Lomitapide—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00136	0.00438	CcSEcCtD
Lomitapide—Fatigue—Fludarabine—lymphatic system cancer	0.00135	0.00437	CcSEcCtD
Lomitapide—Constipation—Fludarabine—lymphatic system cancer	0.00134	0.00433	CcSEcCtD
Lomitapide—Urinary tract disorder—Vincristine—lymphatic system cancer	0.00133	0.0043	CcSEcCtD
Lomitapide—Connective tissue disorder—Vincristine—lymphatic system cancer	0.00133	0.00428	CcSEcCtD
Lomitapide—Urethral disorder—Vincristine—lymphatic system cancer	0.00132	0.00427	CcSEcCtD
Lomitapide—Eye disorder—Carmustine—lymphatic system cancer	0.00132	0.00427	CcSEcCtD
Lomitapide—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.00131	0.00422	CcSEcCtD
Lomitapide—Anaemia—Bleomycin—lymphatic system cancer	0.0013	0.00421	CcSEcCtD
Lomitapide—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00129	0.00418	CcSEcCtD
Lomitapide—Asthenia—Teniposide—lymphatic system cancer	0.00128	0.00414	CcSEcCtD
Lomitapide—Malaise—Bleomycin—lymphatic system cancer	0.00127	0.00411	CcSEcCtD
Lomitapide—Cardiac disorder—Vincristine—lymphatic system cancer	0.00125	0.00404	CcSEcCtD
Lomitapide—Body temperature increased—Fludarabine—lymphatic system cancer	0.00124	0.00401	CcSEcCtD
Lomitapide—Malnutrition—Carmustine—lymphatic system cancer	0.00123	0.00397	CcSEcCtD
Lomitapide—Diarrhoea—Teniposide—lymphatic system cancer	0.00122	0.00395	CcSEcCtD
Lomitapide—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00122	0.00393	CcSEcCtD
Lomitapide—Chest pain—Bleomycin—lymphatic system cancer	0.0012	0.00388	CcSEcCtD
Lomitapide—Myalgia—Bleomycin—lymphatic system cancer	0.0012	0.00388	CcSEcCtD
Lomitapide—Back pain—Carmustine—lymphatic system cancer	0.00119	0.00384	CcSEcCtD
Lomitapide—Discomfort—Bleomycin—lymphatic system cancer	0.00119	0.00383	CcSEcCtD
Lomitapide—Chills—Mitoxantrone—lymphatic system cancer	0.00118	0.00381	CcSEcCtD
Lomitapide—Ecchymosis—Methotrexate—lymphatic system cancer	0.00118	0.00381	CcSEcCtD
Lomitapide—Infection—Bleomycin—lymphatic system cancer	0.00114	0.00369	CcSEcCtD
Lomitapide—Anaemia—Carmustine—lymphatic system cancer	0.00114	0.00367	CcSEcCtD
Lomitapide—Back pain—Vincristine—lymphatic system cancer	0.00114	0.00367	CcSEcCtD
Lomitapide—Vomiting—Teniposide—lymphatic system cancer	0.00114	0.00367	CcSEcCtD
Lomitapide—Asthenia—Fludarabine—lymphatic system cancer	0.00113	0.00364	CcSEcCtD
Lomitapide—Headache—Teniposide—lymphatic system cancer	0.00112	0.00361	CcSEcCtD
Lomitapide—Back pain—Mitoxantrone—lymphatic system cancer	0.00111	0.00357	CcSEcCtD
Lomitapide—Anaemia—Vincristine—lymphatic system cancer	0.00109	0.00351	CcSEcCtD
Lomitapide—Diarrhoea—Fludarabine—lymphatic system cancer	0.00107	0.00347	CcSEcCtD
Lomitapide—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00106	0.00343	CcSEcCtD
Lomitapide—Nausea—Teniposide—lymphatic system cancer	0.00106	0.00343	CcSEcCtD
Lomitapide—Anaemia—Mitoxantrone—lymphatic system cancer	0.00106	0.00342	CcSEcCtD
Lomitapide—Vertigo—Vincristine—lymphatic system cancer	0.00106	0.00341	CcSEcCtD
Lomitapide—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00105	0.00339	CcSEcCtD
Lomitapide—Myalgia—Carmustine—lymphatic system cancer	0.00105	0.00338	CcSEcCtD
Lomitapide—Chest pain—Carmustine—lymphatic system cancer	0.00105	0.00338	CcSEcCtD
Lomitapide—Paraesthesia—Bleomycin—lymphatic system cancer	0.00103	0.00334	CcSEcCtD
Lomitapide—Malaise—Mitoxantrone—lymphatic system cancer	0.00103	0.00333	CcSEcCtD
Lomitapide—Decreased appetite—Bleomycin—lymphatic system cancer	0.001	0.00323	CcSEcCtD
Lomitapide—Myalgia—Vincristine—lymphatic system cancer	0.001	0.00323	CcSEcCtD
Lomitapide—Infection—Carmustine—lymphatic system cancer	0.000998	0.00322	CcSEcCtD
Lomitapide—Vomiting—Fludarabine—lymphatic system cancer	0.000998	0.00322	CcSEcCtD
Lomitapide—Headache—Fludarabine—lymphatic system cancer	0.000983	0.00318	CcSEcCtD
Lomitapide—Myalgia—Mitoxantrone—lymphatic system cancer	0.000974	0.00315	CcSEcCtD
Lomitapide—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000974	0.00315	CcSEcCtD
Lomitapide—Chest pain—Mitoxantrone—lymphatic system cancer	0.000974	0.00315	CcSEcCtD
Lomitapide—Discomfort—Mitoxantrone—lymphatic system cancer	0.000962	0.00311	CcSEcCtD
Lomitapide—Infection—Vincristine—lymphatic system cancer	0.000953	0.00308	CcSEcCtD
Lomitapide—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000948	0.00306	CcSEcCtD
Lomitapide—Nervous system disorder—Vincristine—lymphatic system cancer	0.00094	0.00304	CcSEcCtD
Lomitapide—Nausea—Fludarabine—lymphatic system cancer	0.000932	0.00301	CcSEcCtD
Lomitapide—Infection—Mitoxantrone—lymphatic system cancer	0.000928	0.003	CcSEcCtD
Lomitapide—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000927	0.00299	CcSEcCtD
Lomitapide—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000915	0.00296	CcSEcCtD
Lomitapide—Body temperature increased—Bleomycin—lymphatic system cancer	0.00091	0.00294	CcSEcCtD
Lomitapide—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000907	0.00293	CcSEcCtD
Lomitapide—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000903	0.00292	CcSEcCtD
Lomitapide—Paraesthesia—Carmustine—lymphatic system cancer	0.000902	0.00291	CcSEcCtD
Lomitapide—Somnolence—Carmustine—lymphatic system cancer	0.000893	0.00288	CcSEcCtD
Lomitapide—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.000874	0.00282	CcSEcCtD
Lomitapide—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000874	0.00282	CcSEcCtD
Lomitapide—Decreased appetite—Carmustine—lymphatic system cancer	0.000873	0.00282	CcSEcCtD
Lomitapide—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000867	0.0028	CcSEcCtD
Lomitapide—Paraesthesia—Vincristine—lymphatic system cancer	0.000861	0.00278	CcSEcCtD
Lomitapide—Constipation—Carmustine—lymphatic system cancer	0.000859	0.00277	CcSEcCtD
Lomitapide—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000851	0.00275	CcSEcCtD
Lomitapide—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000839	0.00271	CcSEcCtD
Lomitapide—Decreased appetite—Vincristine—lymphatic system cancer	0.000834	0.00269	CcSEcCtD
Lomitapide—Somnolence—Mitoxantrone—lymphatic system cancer	0.00083	0.00268	CcSEcCtD
Lomitapide—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000828	0.00267	CcSEcCtD
Lomitapide—Feeling abnormal—Carmustine—lymphatic system cancer	0.000828	0.00267	CcSEcCtD
Lomitapide—Fatigue—Vincristine—lymphatic system cancer	0.000827	0.00267	CcSEcCtD
Lomitapide—Asthenia—Bleomycin—lymphatic system cancer	0.000826	0.00267	CcSEcCtD
Lomitapide—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000822	0.00265	CcSEcCtD
Lomitapide—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000821	0.00265	CcSEcCtD
Lomitapide—Constipation—Vincristine—lymphatic system cancer	0.00082	0.00265	CcSEcCtD
Lomitapide—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000812	0.00262	CcSEcCtD
Lomitapide—Fatigue—Mitoxantrone—lymphatic system cancer	0.000805	0.0026	CcSEcCtD
Lomitapide—Constipation—Mitoxantrone—lymphatic system cancer	0.000799	0.00258	CcSEcCtD
Lomitapide—Abdominal pain—Carmustine—lymphatic system cancer	0.000794	0.00256	CcSEcCtD
Lomitapide—Body temperature increased—Carmustine—lymphatic system cancer	0.000794	0.00256	CcSEcCtD
Lomitapide—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.000784	0.00253	CcSEcCtD
Lomitapide—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000784	0.00253	CcSEcCtD
Lomitapide—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00077	0.00249	CcSEcCtD
Lomitapide—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000764	0.00247	CcSEcCtD
Lomitapide—Abdominal pain—Vincristine—lymphatic system cancer	0.000758	0.00245	CcSEcCtD
Lomitapide—Body temperature increased—Vincristine—lymphatic system cancer	0.000758	0.00245	CcSEcCtD
Lomitapide—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000738	0.00238	CcSEcCtD
Lomitapide—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000738	0.00238	CcSEcCtD
Lomitapide—Vomiting—Bleomycin—lymphatic system cancer	0.000732	0.00236	CcSEcCtD
Lomitapide—Infestation—Methotrexate—lymphatic system cancer	0.00073	0.00236	CcSEcCtD
Lomitapide—Infestation NOS—Methotrexate—lymphatic system cancer	0.00073	0.00236	CcSEcCtD
Lomitapide—Asthenia—Carmustine—lymphatic system cancer	0.000721	0.00233	CcSEcCtD
Lomitapide—Haematuria—Methotrexate—lymphatic system cancer	0.000696	0.00225	CcSEcCtD
Lomitapide—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.00069	0.00223	CcSEcCtD
Lomitapide—Asthenia—Vincristine—lymphatic system cancer	0.000688	0.00222	CcSEcCtD
Lomitapide—Diarrhoea—Carmustine—lymphatic system cancer	0.000687	0.00222	CcSEcCtD
Lomitapide—Nausea—Bleomycin—lymphatic system cancer	0.000684	0.00221	CcSEcCtD
Lomitapide—Asthenia—Mitoxantrone—lymphatic system cancer	0.00067	0.00216	CcSEcCtD
Lomitapide—Dizziness—Carmustine—lymphatic system cancer	0.000664	0.00215	CcSEcCtD
Lomitapide—Diarrhoea—Vincristine—lymphatic system cancer	0.000656	0.00212	CcSEcCtD
Lomitapide—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000647	0.00209	CcSEcCtD
Lomitapide—Urethral disorder—Methotrexate—lymphatic system cancer	0.000642	0.00207	CcSEcCtD
Lomitapide—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000639	0.00206	CcSEcCtD
Lomitapide—Vomiting—Carmustine—lymphatic system cancer	0.000639	0.00206	CcSEcCtD
Lomitapide—Dizziness—Vincristine—lymphatic system cancer	0.000634	0.00205	CcSEcCtD
Lomitapide—Headache—Carmustine—lymphatic system cancer	0.000629	0.00203	CcSEcCtD
Lomitapide—Eye disorder—Methotrexate—lymphatic system cancer	0.000612	0.00198	CcSEcCtD
Lomitapide—Vomiting—Vincristine—lymphatic system cancer	0.00061	0.00197	CcSEcCtD
Lomitapide—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000608	0.00196	CcSEcCtD
Lomitapide—Headache—Vincristine—lymphatic system cancer	0.000601	0.00194	CcSEcCtD
Lomitapide—Nausea—Carmustine—lymphatic system cancer	0.000597	0.00193	CcSEcCtD
Lomitapide—Vomiting—Mitoxantrone—lymphatic system cancer	0.000594	0.00192	CcSEcCtD
Lomitapide—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.00059	0.00191	CcSEcCtD
Lomitapide—Chills—Methotrexate—lymphatic system cancer	0.000588	0.0019	CcSEcCtD
Lomitapide—Headache—Mitoxantrone—lymphatic system cancer	0.000585	0.00189	CcSEcCtD
Lomitapide—Malnutrition—Methotrexate—lymphatic system cancer	0.00057	0.00184	CcSEcCtD
Lomitapide—Nausea—Vincristine—lymphatic system cancer	0.00057	0.00184	CcSEcCtD
Lomitapide—Nausea—Mitoxantrone—lymphatic system cancer	0.000555	0.00179	CcSEcCtD
Lomitapide—Back pain—Methotrexate—lymphatic system cancer	0.000551	0.00178	CcSEcCtD
Lomitapide—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000529	0.00171	CcSEcCtD
Lomitapide—Anaemia—Methotrexate—lymphatic system cancer	0.000527	0.0017	CcSEcCtD
Lomitapide—Malaise—Methotrexate—lymphatic system cancer	0.000514	0.00166	CcSEcCtD
Lomitapide—Vertigo—Methotrexate—lymphatic system cancer	0.000512	0.00165	CcSEcCtD
Lomitapide—Myalgia—Methotrexate—lymphatic system cancer	0.000485	0.00157	CcSEcCtD
Lomitapide—Chest pain—Methotrexate—lymphatic system cancer	0.000485	0.00157	CcSEcCtD
Lomitapide—Arthralgia—Methotrexate—lymphatic system cancer	0.000485	0.00157	CcSEcCtD
Lomitapide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000482	0.00156	CcSEcCtD
Lomitapide—Discomfort—Methotrexate—lymphatic system cancer	0.00048	0.00155	CcSEcCtD
Lomitapide—Infection—Methotrexate—lymphatic system cancer	0.000462	0.00149	CcSEcCtD
Lomitapide—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000456	0.00147	CcSEcCtD
Lomitapide—Skin disorder—Methotrexate—lymphatic system cancer	0.000452	0.00146	CcSEcCtD
Lomitapide—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.00045	0.00145	CcSEcCtD
Lomitapide—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000424	0.00137	CcSEcCtD
Lomitapide—Paraesthesia—Methotrexate—lymphatic system cancer	0.000418	0.00135	CcSEcCtD
Lomitapide—Somnolence—Methotrexate—lymphatic system cancer	0.000414	0.00134	CcSEcCtD
Lomitapide—Dyspepsia—Methotrexate—lymphatic system cancer	0.00041	0.00132	CcSEcCtD
Lomitapide—Decreased appetite—Methotrexate—lymphatic system cancer	0.000404	0.00131	CcSEcCtD
Lomitapide—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000402	0.0013	CcSEcCtD
Lomitapide—Fatigue—Methotrexate—lymphatic system cancer	0.000401	0.0013	CcSEcCtD
Lomitapide—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000383	0.00124	CcSEcCtD
Lomitapide—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.00038	0.00123	CcSEcCtD
Lomitapide—Body temperature increased—Methotrexate—lymphatic system cancer	0.000368	0.00119	CcSEcCtD
Lomitapide—Abdominal pain—Methotrexate—lymphatic system cancer	0.000368	0.00119	CcSEcCtD
Lomitapide—Asthenia—Methotrexate—lymphatic system cancer	0.000334	0.00108	CcSEcCtD
Lomitapide—Diarrhoea—Methotrexate—lymphatic system cancer	0.000318	0.00103	CcSEcCtD
Lomitapide—Dizziness—Methotrexate—lymphatic system cancer	0.000308	0.000994	CcSEcCtD
Lomitapide—Vomiting—Methotrexate—lymphatic system cancer	0.000296	0.000955	CcSEcCtD
Lomitapide—Headache—Methotrexate—lymphatic system cancer	0.000291	0.000941	CcSEcCtD
Lomitapide—Nausea—Methotrexate—lymphatic system cancer	0.000276	0.000892	CcSEcCtD
